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Abstract
Being protein function a conformation-dependent issue, avoiding aggregation during production is a major
challenge in biotechnological processes, what is often successfully addressed by convenient upstream, midstream
or downstream approaches. Even when obtained in soluble forms, proteins tend to aggregate, especially if stored
and manipulated at high concentrations, as is the case of protein drugs for human therapy. Post-production
protein aggregation is then a major concern in the pharmaceutical industry, as protein stability, pharmacokinetics,
bioavailability, immunogenicity and side effects are largely dependent on the extent of aggregates formation. Apart
from acting at the formulation level, the recombinant nature of protein drugs allows intervening at upstream
stages through protein engineering, to produce analogue protein versions with higher stability and enhanced
therapeutic values.
Aggregation and associated conformational stress of cell
factories (both prokaryotic and eukaryotic) are major
concerns in recombinant protein production, resulting
in low yields, unstable production and limited solubility
and biological activity of the products [1-9]. Basic
research on protein folding and the routine implementa-
tion of several analytical procedures such as circular
dichroism, mass spectrometry and infrared spectroscopy
(mostly incorporated from amyloid research) [4,10-16]
have expanded our understanding of how polypeptide
chains cross-interact and aggregate in vivo. In bacteria,
probably the most studied cell factories, aggregation as
inclusion bodies, a quite common event during produc-
tion of heterologous polypeptides [17,18], is now
observed as a complex physiological event in which cel-
lular agents, including chaperones [6,19,20], proteases
[21-23] and actin-like proteins [24] are coordinately act-
ing [24,25] in the frame of the cell’s protein quality con-
trol machinery [26-28]. Despite aggregation as inclusion
bodies might represent a source of relatively pure pro-
teins for further refolding or extraction [29-33], or
unexpectedly, a new type of nano-microparticulate bio-
materials for biotechnological and biomedical applica-
tions [34-39], the use of recombinant proteins for most
of biotechnological and biomedical applications requires
fully soluble protein versions. A particular issue in
recombinant protein aggregation is the occurrence of
soluble aggregates (less apparent that large aggregates),
that are being progressively recognized in production
processes. These soluble clusters adopt a spectrum of
forms (mainly fibrilar, spherical or amorphous) [40,41]
and might be the in vivo physiological precursors and
structural components of bacterial inclusion bodies
[24,42]. Very different approaches have been explored at
upstream, midstream and downstream levels to mini-
mize aggregation during recombinant protein produc-
tion (Figure 1). Such strategies, eventhough being
mostly a trial-and-error process, often result in signifi-
cant improvements of protein solubility [43-46].
Desirably, soluble versions of recombinant proteins
should keep such soluble status in post-production
stages, that is, during storage and use. This need is spe-
cially acute in the case of proteins intended for thera-
peutic uses [47,48]. Protein drugs are commonly
administered parenterally [49], what makes protein
aggregation in stocks or upon administration a main
concern in the Pharma industry (see for instance, http://
www.eahp.eu/content/download/25193/164355/.../Cov-
erStory20-21.pdf.pd). The high concentration at which
proteins drugs are stored and administered [50] specifi-
cally favors aggregation [51]. In this context, diverse
analytical procedures have been developed and
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any medium, provided the original work is properly cited.specifically adapted to the detection of therapeutic pro-
tein aggregation [52-54]. Importantly, aggregation does
not only render drug inactivation during storage, and
fast clearance, reduction of activity, limited bioavailabil-
ity and proteolytic digestion upon administration, but it
also stimulates undesired immunogenicity [55]. This is a
critical issue in clinics as severe side effects observed
upon prolonged protein administration (as in the case of
insulins, interferons, erythropoietin and growth hor-
mone) are antibody-dependent [56-59].
Chemical modification of proteins and the use of
appropriate excipients (Figure 1) are the most taken
approaches for protein drug stabilization [60-62].
Obviously, emerging concepts in Nanotechnology,
Nanomedicine and in Material Sciences offer new bio-
compatible vehicles for protein encapsulation or
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Figure 1 Tool boxes through which protein solubility can be enhanced at different stages of protein production and postproduction
pipelines. Targets for improvement during in vivo administration are summarized in the red framed box, some of them being modulated by
protein aggregation. Appropriate codon selection [82,83], using weak promoters or low copy number plasmids and protein engineering [84] are
the most common upstream strategies (yellow box). Growth at sub-optimal temperatures [85,86], mild induction of gene expression, co-
production of chaperones [87-89] or protein production in protease-deficient strains [90,91] or in mutants with altered redox properties [92] favor
correct protein folding (orange box). Buffers and purification conditions should be optimized as per protein basis to prevent aggregation [93-97].
Alternatively, soluble protein species can be obtained by refolding inclusion body proteins [30-32] or by extracting functional proteins from
inclusion bodies by mild procedures [29] (green box). Once purified, aggregation during storage or administration of protein drugs can be
inhibited by appropriate excipient formulations or by chemical modification [50,60,62,98] (blue box). Also, the use of delivery systems, either
through protein adsorption onto nanoparticles, nano and micro encapsulation or embedding in biocompatible materials stabilize proteins,
expand their half-life in the body and permit a sustained release, resulting in enhanced bioavailability and reduced toxicity [63,64,99]. Upstream
protein engineering strategies that enhance solubility during production can also affect aggregation and performance of protein drugs upon
administration. Also, by this approach, novel functions that improve pharmacological performance of proteins can be gained without necessarily
enhancing solubility (bottom, green framed box).
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stability, tissue targeting and bioavailability during drug
delivery are dramatically enhanced [63,64]. Many among
those such nanostructured materials are from bacterial
origin [65].
Being proteins flexible molecules suitable to be re-
designed by genetic methods, upstream protein engi-
neering, one of the main approaches to prevent aggrega-
tion during production (Table 1, up), is also useful to
stabilize protein drugs during use (Table 1, bottom). In
addition, modification of the protein primary sequence
permits a fine tuning of protein features such as oligo-
merization, activity, cell targeting and cell penetration,
that represent additional values in the performance of a
protein drug (Table 1; Figure 1, bottom). In this regard,
protein engineering is revealed as an extremely flexible
approach to enhance the stability of proteins during
production, storage and use, but also to improve their
performance in in vivo uses. Reduction of aggregation is
expected to minimize immunogenicity, increase proteo-
lytic stability, improve bioavailability and limit side-
effects, as aggregation has a pivotal role in all these
issues [55,59,66-69]. In addition, protein modification
can offer added values to protein drugs, by conferring
novel functions that improve pharmacological perfor-
mance without necessarily enhancing solubility (Figure
1, green framed box). These include cell or tissue target-
ing or enhanced cell penetration by the fusion to a cell
receptor ligand or an antibody [70-74], enhancing half-
life and bioavailability by fusion to transferrin [75], albu-
min [76], or albumin-binding peptides [77] and crossing
the brain-blood barrier (BBB) by the incorporation of
cationic peptides [78]. Creating multifunctional proteins
by the appropriate combination of protein domains in a
single polypeptide chain is being especially explored for
the construction of protein-only artificial viruses, in
Table 1 Protein engineering strategies to reduce aggregation or derived effects during either production or
administration, illustrated by representative examples.
Protein engineering strategy Result Protein Reference
Improving protein folding during production
Cys®Ser point mutations Reduced aggregation, enhanced proteolytic
stability
bFGF
a [100]
Point mutations in an hydrophobic stretch Reduced aggregation 11 beta-HSD1 [101]
Directed evolution/point mutations Reduced aggregation Cytochrome P450sca-2 [102]
Fusion of SUMO tag Improved refolding Fgf15 [103]
Polycationic amino acid tag fusion Reduced aggregation Candida antarctica
lipase B
[104]
Fusion to polylysines or polyarginines Reduced aggregation BPTI-22 [105]
Fusion to MBP Reduced aggregation Ribonuclease inhibitor [106]
Fusion to GrpE Reduced aggregation hIL-3 [107]
Fusion to NusA Reduced aggregation, enhanced proteolytic
stability
E8R viral protein [108]
Improving protein folding, stability and performance
during administration
Single amino acid substitution Inhibited oligomer formation; enhanced
bioavailability
Insulin Aspart
® [109]
Single amino acid substitution Improved folding INF-b-1b (Betaferon
®) [110]
N-terminal peptide deletion Enhanced stability KGF [111]
Fusion with albumin Extended half-life Albinterferon a-2b [76]
Fusion with transferrin Enhanced gastrointestinal adsorption hGH [75]
Artificial consensus protein sequence Enhanced activity Interferon acon-1
(Infergen
®)
[112]
Fusion of a HIV Tat segment Enhanced solubility p53 [113]
Fusion of a HIV Tat protein and ODD Enhanced stability and activity in hypoxic
tumor cells
Casp-3 [114]
Fusion of a HIV Tat protein and sequence modification Cell penetration and selective activation in HIV-
infected cells
Casp-3 [115]
Ligand incorporation (mainly antibody fragments) Enhanced stability and bioavailbility IL-2 [71]
a Abbreviations are: 11 beta-HSD1, 11 beta-Hydroxysteroid dehydrogenase type 1; aFGF, acidic fibroblast growth factor; bFGF: Fgf15, Fibroblast growth factor 15;
BPTI-22, Bovine pancreatic trypsin inhibitor variant 22; Casp-3, caspase 3; HIV, human immunodeficiency virus; hFGF, Human basic fibroblast growth factor; BSA,
bovine serum albumin; HAS, human serum albumin; hGH, human growth hormone; hIL-3, human interleukin-3; KGF, keratinocyte growth factor; IL, interleukin;
MAGOH, Protein mago nashi homolog; MBP, maltose-binding protein; OOD, oxygen-dependent degradation domain of hypoxia-inducible factor-1alpha; rhDNase,
recombinant human DNAse; SUMO, small ubiquitin-related modifier.
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chimerical protein building blocks [72,79-81]. Further
exploration of protein engineering focused on post-pro-
duction issues is strongly required and it should allow
the emergence of optimized drugs to fulfill their increas-
ing demand.
Conclusions
Stability and solubility of recombinant proteins is a criti-
cal issue at both production and post-production stages.
For a biomedical use of proteins as pharmaceuticals,
high solubility not only supports stability but it also
enhances bioavailability and reduces immunogenicity
and undesired toxic effects. Among other approaches to
stabilize protein drugs, such as chemical modification,
proper formulation and encapsulation, protein engineer-
ing is a very flexible route to improve protein folding
during production and reduce aggregation during sto-
rage and in vivo. Furthermore, the modification of pro-
tein primary sequence permits to confer additional
functional values, such as binding to serum albumin,
binding to cell surface receptors and cell membrane (or
BBB) crossing, thus improving biodistribution, expand-
ing the half-life and enhancing the biological potential
of the drug. The wide spectrum of possibilities of post-
production-addressed protein engineering is probably to
be yet realized.
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